Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction?
WH van Gilst, JH Kingma, KH Peels, JH Dambrink, and M St John Sutton CATS Coordination Center, St. Antonious Hospital, Nieuwegein, The Netherlands. OBJECTIVES: In this study we sought to investigate the effect of intervention with captopril within 6 h of the onset of myocardial infarction on left ventricular volume and clinical symptoms of heart failure in relation to infarct size during a 1-year follow-up period. BACKGROUND: Remodeling of the heart starts in the early phase of myocardial infarction and is associated with an adverse prognosis. Angiotensin-converting enzyme inhibition started in the subacute or late phase after myocardial infarction has been shown to improve prognosis. METHODS: In the Captopril and Thrombolysis Study, 298 patients with a first anterior myocardial infarction treated with intravenous streptokinase were randomized to receive either oral captopril (25 mg three times a day) or placebo. The left ventricular volume index was assessed by two-dimensional echocar
Related Questions
- Is ramipril really better than other angiotensin-converting enzyme inhibitors after acute myocardial infarction?
- Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction?
- Why does a patient become sweaty, pallid and tachycardic during an acute myocardial infarction?
